Clinical Trial Update: Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update examining whether the COMT Val108/Met genetic polymorphism influences smoking cessation outcomes with nicotine replacement therapy; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Snippet

Sponsor: National Institute on Drug Dependence, China | Conditions: Nicotine Dependence | Phase 4 | Status: COMPLETED